false 0001129928 0001129928 2026-11-19 2026-11-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 19, 2026

 

 

 

Oncolytics Biotech Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Nevada 001-38512 98-0541667
(State or other jurisdiction of
incorporation)
(Commission File Number) (IRS Employer Identification No.)

 

4350 Executive Drive, Suite 325

San Diego, CA 92121

92121
(Address of principal executive offices) (Zip Code)
   
(403) 670-7377
(Registrant's telephone number, including area code)
 
N/A
(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
         
Common stock, par value $0.001 per share   ONCY   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On November 19, 2026, the Company held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) at 4:00 p.m. Eastern Time by means of an online virtual meeting platform. There were 131,120,719 shares of common stock outstanding on the record date. Stockholders representing 65,061,822, or 49.61%, of the 131,120,719 votes outstanding were represented in person or by proxy constituting a quorum.

 

At the 2026 Annual Meeting, the following proposals were approved: (i) the election of seven directors to hold office until the 2027 annual meeting; (ii) the ratification of the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026; and (iii) the advisory vote on the compensation of the Company’s named executive officers. The Board’s recommendation to hold the advisory frequency vote on the compensation of the Company’s named executive officers every three years did not receive a majority of the votes cast. The Board values the opinion of the Company’s stockholders and has taken into consideration the recommendation of the Company’s stockholders to hold an advisory vote on executive compensation every year. After consideration, the Board has determined, and believe it to be in the best interest of the Company, to hold an advisory vote on executive compensation every three years, or until the Board otherwise determines that a different frequency for such advisor vote is in the best interest of the stockholders of the Company. These proposals are described in detail in the Company’s definitive proxy statement on Schedule 14A for the 2026 Annual Meeting filed with the SEC on October 6, 2026.

 

Proposal 1

 

The votes with respect to the election of seven directors to hold office until the 2027 annual meeting were as follows:

 

Director  For   % Voted For   Withheld   % Voted
Withheld
   Broker Non-
Votes
 
Jared Kelly   21,465,185    89.54%   2,508,575    10.46%   41,088,062 
Bernd R. Seizinger   21,380,239    89.18%   2,593,521    10.82%   41,088,062 
Deborah M. Brown   21,572,684    89.98%   2,401,076    10.02%   41,088,062 
James T. Parsons   20,724,255    86.45%   3,249,505    13.55%   41,088,062 
Jonathan Rigby   21,506,444    89.71%   2,467,316    10.29%   41,088,062 
Patricia S. Andrews   21,669,279    90.39%   2,304,481    9.61%   41,088,062 
Stephen Glover   21,624,838    90.20%   2,348,922    9.80%   41,088,062 

 

Proposal 2

 

The votes with respect to the ratification of KPMG LLP as the Company’s independent registered accounting firm for the year ending December 31, 2026, were as follows:

 

Total Votes For  Total Votes Against   Abstentions   Broker Non-Votes 
62,887,796   1,694,520    479,506    - 

 

 

 

Proposal 3

 

The votes with respect to the advisory vote to approve the compensation of the Company’s named executive officers were as follows:

 

Total Votes For  Total Votes Against   Abstentions   Broker Non-Votes 
13,559,766   9,777,095    636,899    41,088,062 

 

Proposal 4

 

The votes with respect to the advisory vote on the frequency of the advisory vote on the compensation of the Company’s named executive officers were as follows:

 

3 Years  2 Years   1 Year   Abstentions   Broker Non-Votes 
9,781,900   1,485,942    11,319,330    1,386,588    - 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 20, 2026

 

  ONCOLYTICS BIOTECH INC.
   
  By: /s/ Kirk Look
  Name: Kirk Look
  Title: Chief Financial Officer